<DOC>
	<DOCNO>NCT00531232</DOCNO>
	<brief_summary>There well accept standard care patient fail intolerant currently approve therapy Myelodysplastic Syndromes ( MDS ) . In study , patient assign receive 25mg oral clofarabine daily 5 day . Patients may receive 8 cycle treatment clofarabine long patient continue benefit absence progressive disease .</brief_summary>
	<brief_title>A Dose Confirmation Study Oral Clofarabine Adult Patients Previously Treated Myelodysplastic Syndromes ( MDS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>Have pathologically confirm secondary Acute Myeloid Leukemia ( follow history MDS ) MDS intermediate 1 ( marrow blast great equal 5 % ) intermediate 2 high risk score assess International Prognostic Scoring System ( IPSS ) study , entry . Patients refractory anemia excess blast transformation ( RAEBt ) recognize FrenchAmericanBritish ( FAB ) system , chronic myelomonocytic leukemia ( CMML ) allow study . Pathologic confirmation responsibility site investigator . Have previously treat MDS define follow : . ) Patients must least one , two , prior treatment regimen [ A treatment regimen define drug drug combination administer treatment MDS intent induce least hematologic improvement ( consistent International Working Group [ IWG ] criterion ) ; Inadequate treatment , due drug intolerance factor , still consider prior treatment regimen . Hematopoietic growth factor , hydroxyurea , antithymocyte globulin ( ATG ) , supportive care measure ( e.g. , blood transfusion , immunosuppressive agent , antibiotic ) consider treatment regimen purpose study entry . ] b . ) One treatment regimens must either 5azacytidine decitabine . If 5azacytidine decitabine give treatment regimen , consider 2 different treatment regimen . c. ) Patients must refractory ( i.e. , progression disease , evidence response , treatment ) one prior treatment regimen ( consider refractory decitabine 5azacitidine , patient must receive great equal 4 cycle ) . Have documentation prior transfusion requirement precede 8 week ( 8 week prior first dose study drug ) . Have Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Be able comply study procedure followup examination . Have adequate renal hepatic function indicate predefined laboratory value : . ) Total bilirubin &lt; 1.5 x institutional Upper Limit Normal ( ULN ) except unconjugated hyperbilirubin secondary treatment MDS Gilbert 's syndrome ; b . ) Aspartate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) &lt; 2.5 x ULN ; c. ) Serum creatine &lt; 1.0 mg/dL , estimate glomerular filtration rate ( GFR ) must &gt; 30 mL/min/1.73 m2 calculate Modification Diet Renal Disease ( MDRD ) equation . Be nonfertile agree use birth control study end last treatment visit least 90 day . Have adjustment dose and/or schedule erythropoietin , granulocyte colony stimulate factor ( GCSF ) growth factor within 8 week prior first dose oral clofarabine . Have prior therapy treatment sAML . Hydroxyurea must receive within 24 hour prior first dose study drug . Have chemotherapy investigational therapy within four week first dose study drug . Have prior pelvic radiotherapy . Have prior hematopoietic stem cell transplant MDS . Have recover &lt; grade 2 drugrelated nonhematologic toxicity prior first dose study drug . Have uncontrolled systemic fungal , bacterial , viral , infection ( define exhibit ongoing signs/symptoms related infection without improvement , despite appropriate antibiotic treatment ) . Have psychiatric disorder would interfere consent , study participation , followup . Have severe concurrent disease , history serious organ dysfunction disease involve heart , kidney , liver , particular : . ) New York Heart Association ( NHA ) classification stage II , III , IV congestive heart failure ; b . ) Coronary artery disease arteriosclerotic cardiovascular disease ( angina , myocardial infraction ) within 3 month first dose study drug ; c. ) Any primary cardiac disease , opinion investigator , increase risk ventricular arrhythmia . Have severe concurrent disease , history serious organ dysfunction disease involve heart prior treatment Clofarabine . Have diagnosis another malignancy , unless patient diseasefree least 3 year follow completion curative intent therapy follow exception : . ) Patients treat nonmelanoma skin cancer , situ carcinoma , cervical intraepithelial neoplasia , regardless disease free duration , eligible study definitive treatment condition complete . b . ) Patients organconfined prostate cancer evidence recurrent progressive disease base prostatespecific antigen ( PSA ) value also eligible study hormonal therapy initiate radical prostatectomy perform . Have prior positive test Human Immunodeficiency Virus ( HIV ) . Have currently active gastrointestinal disease , prior surgery may affect ability patient absorb oral clofarabine . Participating concurrent investigational protocol restrict data and/or sample collection patient demographic and/or sample collection patient demographic and/or disease purpose . Have prior treatment know nephrotoxic drug within 2 week first dose study drug , unless patient calculate GFR &gt; 30 2 time point less 7 day apart 2week period prior first dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Previously treat Myelodysplastic Syndromes ( MDS )</keyword>
	<keyword>oral clofarabine</keyword>
	<keyword>Intermediate-1 , Intermediate-2 High Risk Myelodysplastic Syndromes ( MDS )</keyword>
	<keyword>secondary AML ( history MDS )</keyword>
</DOC>